Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Kos’ Integrated Sales Force Expected To Accelerate Niaspan Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott says there will be “synergistic” effects from folding Niaspan into its cholesterol portfolio that will improve sales over those seen when Kos was the sole marketer.

You may also be interested in...



New Niaspan Tablets Gain FDA Approval

Coated tablet version of Abbott’s cholesterol therapy reduces flushing, firm claims.

New Niaspan Tablets Gain FDA Approval

Coated tablet version of Abbott’s cholesterol therapy reduces flushing, firm claims.

Abbott Targets Simcor Filing For First Half 2007

Addition of Kos nearly doubles Abbott's 2007 dyslipidemia franchise.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel